Morgens Waterfall Vintiadis & Co. Inc. Raises Stake in Axon Enterprise, Inc. (NASDAQ:AXON)

Morgens Waterfall Vintiadis & Co. Inc. boosted its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 12.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,000 shares of the biotechnology company's stock after buying an additional 1,100 shares during the quarter. Axon Enterprise accounts for about 4.5% of Morgens Waterfall Vintiadis & Co. Inc.'s holdings, making the stock its 11th biggest holding. Morgens Waterfall Vintiadis & Co. Inc.'s holdings in Axon Enterprise were worth $5,943,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Axon Enterprise by 1.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 12,607 shares of the biotechnology company's stock valued at $7,493,000 after purchasing an additional 185 shares during the period. Czech National Bank boosted its stake in shares of Axon Enterprise by 7.4% in the fourth quarter. Czech National Bank now owns 15,707 shares of the biotechnology company's stock valued at $9,335,000 after purchasing an additional 1,082 shares during the period. Brookstone Capital Management boosted its stake in shares of Axon Enterprise by 27.0% in the fourth quarter. Brookstone Capital Management now owns 974 shares of the biotechnology company's stock valued at $579,000 after purchasing an additional 207 shares during the period. MRA Advisory Group boosted its stake in shares of Axon Enterprise by 64.4% in the fourth quarter. MRA Advisory Group now owns 3,205 shares of the biotechnology company's stock valued at $1,905,000 after purchasing an additional 1,255 shares during the period. Finally, 180 Wealth Advisors LLC acquired a new stake in Axon Enterprise in the fourth quarter valued at approximately $220,000. Hedge funds and other institutional investors own 79.08% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on AXON shares. The Goldman Sachs Group raised their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a report on Wednesday. Craig Hallum cut shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a report on Monday, March 10th. JMP Securities reaffirmed an "outperform" rating on shares of Axon Enterprise in a report on Tuesday, February 4th. Northcoast Research cut shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a report on Wednesday, February 19th. Finally, Barclays raised their target price on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $652.73.

Insider Activity at Axon Enterprise

In related news, President Joshua Isner sold 9,000 shares of Axon Enterprise stock in a transaction on Monday, May 12th. The shares were sold at an average price of $683.31, for a total value of $6,149,790.00. Following the transaction, the president now directly owns 308,714 shares in the company, valued at $210,947,363.34. This trade represents a 2.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jeri Williams sold 307 shares of Axon Enterprise stock in a transaction on Monday, March 17th. The shares were sold at an average price of $552.72, for a total transaction of $169,685.04. Following the completion of the transaction, the director now owns 1,627 shares in the company, valued at approximately $899,275.44. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 23,764 shares of company stock worth $14,856,635 in the last three months. Insiders own 4.40% of the company's stock.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock traded up $4.79 during trading on Friday, reaching $733.18. The company's stock had a trading volume of 419,101 shares, compared to its average volume of 759,084. The company has a 50-day moving average price of $584.61 and a two-hundred day moving average price of $593.44. The firm has a market cap of $57.08 billion, a PE ratio of 189.45, a P/E/G ratio of 5.17 and a beta of 1.24. Axon Enterprise, Inc. has a fifty-two week low of $273.52 and a fifty-two week high of $735.68. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, beating analysts' consensus estimates of $1.34 by $0.07. The business had revenue of $603.63 million for the quarter, compared to analysts' expectations of $585.67 million. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The company's quarterly revenue was up 31.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.15 EPS. On average, analysts forecast that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.